What are the Circulating Tumor Cells?
CTC is the main tumor-shedding cancer cells that intravasate into the peripheral blood circulation system, causing metastasis. These are the cancer cells that have detached from the primary tumor and entered the bloodstream. CTC is considered to be a key component in the metastasis
Drivers of Circulating Tumor Cells Market
Immune system invasion: Cancer cells can evade immune surveillance mechanisms and immune-mediated destruction they may down-regulate the cell surface proteins involved in immune recognition or activate immune checkpoint pathways, allowing them to escape immune detection and elimination
Angiogenesis: angiogenesis is the process of new blood vessel formation. Tumors induce angiogenesis to ensure a sufficient blood supply for their growth. the newly formed blood vessels are often abnormal, leaky, and lack a proper basement membrane, allowing CTCs to enter the bloodstream more easily
Restraining factors
Technological challenges: The development of accurate and reliable technologies for detecting and analyzing CTCs is complex. The technologies must be sensitive enough to detect rare CTCs among a large number of normal blood cells. Overcoming these technological challenges and ensuring consistent reproducible results
Heterogeneity of CTCs: CTCs exhibit significant heterogeneity both in terms of their molecular characteristics and physical properties. This heterogeneity makes it challenging to develop standardized approaches for their detection and analysis. The lack of standardized protocols and methods can hinder the widespread adoption of CTC- based diagnosis
Clinical Utility and value proposition: Demonstrating the clinical utility and value proposition of CTCS-based technologies compared to existing diagnostic and monitoring approaches is essential for market adoption. It also has the ability to provide actionable information for treatment.
Recent development
Increased Growth in the tumor cell market:
As per the recent update from Global Newswire, revenue is expected to increase from $9.5 billion to $10.7 billion in 2023. As there is growth in the market size of cancer about $16.7 billion in 2027, due to the rising incidence of cancer and spreading the growing incidence of cancer is fueling the market growth.
Conclusion
CTCs offer a non-invasion method for monitoring cancer progression, assessing treatment response, and predicting patient outcomes by capturing and analyzing CTCs. Furthermore, the enumeration and characterization of CTCs have the potential to guide treatment decisions allowing for the selection.
Author's Detail:
Anushka Gore /
LinkedIn
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations.
In her current role, Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses. Her collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization.Anushka remains an invaluable asset in the dynamic landscape of market research.
